


## Sulfosuccinimidyl oleate sodium

Cat. No.:	HY-112847A		
Molecular Formula:	C <sub>22</sub> H <sub>36</sub> NNaO <sub>7</sub> S		
Molecular Weight:	481.58		
Target:	Others		
Pathway:	Others		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 62.5 mg/mL (129.78 mM; Need ultrasonic)  
 H<sub>2</sub>O : < 0.1 mg/mL (insoluble)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	2.0765 mL	10.3825 mL	20.7650 mL
	5 mM	0.4153 mL	2.0765 mL	4.1530 mL
	10 mM	0.2076 mL	1.0382 mL	2.0765 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: **10% DMSO >> 90% corn oil**  
 Solubility: ≥ 2.08 mg/mL (4.32 mM); Clear solution
- Add each solvent one by one: **10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline**  
 Solubility: ≥ 2.08 mg/mL (4.32 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

Sulfosuccinimidyl oleate sodium is a long chain fatty acid that inhibits fatty acid transport into cells. Sulfosuccinimidyl oleate binds the **CD36 receptor** on the surface of microglia. Anti-inflammatory effect<sup>[1]</sup>.

#### In Vitro

Sulfosuccinimidyl oleate (20 μM and 50 μM, 24 hours) alone does not alter the cellular viability. Exposure to 100 ng/ml LPS+5 ng/ml IFNγ modestly, yet significantly reduces the viability of the BV2 cells. Co-treatment with Sulfosuccinimidyl oleate prevents the LPS+IFNγ-induced reduction in the cell viability<sup>[1]</sup>. Sulfosuccinimidyl oleate (50 μM, 24 hours) co-treatment significantly reduces the LPS+IFNγ-induced expression of NOS2 and COX-2 in BV2 cells. Western blot analysis reveals a significant LPS/IFNγ-induced upregulation in the phosphorylated form of the p38, which is prevented by co-treatment with Sulfosuccinimidyl oleate (50 μM, 24 hours)

[1].

#### Cell Viability Assay<sup>[1]</sup>

Cell Line:	BV2 cells
Concentration:	20 $\mu$ M and 50 $\mu$ M
Incubation Time:	24 hours
Result:	Did not alter the viability of BV2 cells alone. Exposure of BV2 cells to 100 ng/mL LPS and 5 ng/mL IFN $\gamma$ significantly reduced the viability of BV2 cells while simultaneous treatment with Sulfosuccinimidyl oleate prevented it.

#### Western Blot Analysis<sup>[1]</sup>

Cell Line:	BV2 cells
Concentration:	50 $\mu$ M
Incubation Time:	24 hours
Result:	Drastically increased the levels of NOS2, COX-2, and P-p38/T-p38.

#### In Vivo

Sulfosuccinimidyl oleate (50 mg/kg; administered once by single oral gavage) significantly reduces the cortical ischemic infarct size compared to vehicle-treated controls in male BALB/cABom mice with pMCAo model. In addition, Sulfosuccinimidyl oleate at 50 mg/kg is suitable to see a beneficial effect after stroke<sup>[1]</sup>.

Animal Model:	4-month-old male BALB/cABom mice with pMCAo model <sup>[1]</sup>
Dosage:	50 mg/kg
Administration:	Administered once by single oral gavage
Result:	Reduced brain damage following ischemia. Attenuated infarct size.

## REFERENCES

[1]. Dhungana H, et al. Sulfosuccinimidyl oleate sodium is neuroprotective and alleviates stroke-induced neuroinflammation. J Neuroinflammation. 2017 Dec 4;14(1):237.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA